Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at Leerink Partnrs cut their Q3 2024 earnings estimates for shares of Pyxis Oncology in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now expects that the company will earn ($0.35) per share for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04.

PYXS has been the subject of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Finally, Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $9.00.

Pyxis Oncology Trading Up 16.1 %

Pyxis Oncology stock opened at $3.75 on Friday. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85. The stock has a fifty day simple moving average of $3.54 and a two-hundred day simple moving average of $3.78. The firm has a market cap of $222.83 million, a price-to-earnings ratio of -3.02 and a beta of 1.27.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Fullcircle Wealth LLC purchased a new stake in shares of Pyxis Oncology in the 2nd quarter worth $40,000. SG Americas Securities LLC bought a new stake in Pyxis Oncology during the first quarter valued at about $59,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology in the second quarter worth about $65,000. Schulhoff & Co. Inc. raised its stake in shares of Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after buying an additional 20,000 shares during the period. Finally, American Century Companies Inc. lifted its position in shares of Pyxis Oncology by 56.0% during the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after buying an additional 20,901 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.